share_log

Virpax Pharmaceuticals | 8-K: Current report

Virpax Pharmaceuticals | 8-K: Current report

Virpax制药 | 8-K:重大事件
美股SEC公告 ·  09/17 16:15

Moomoo AI 已提取核心信息

Virpax Pharmaceuticals, Inc., a Delaware-incorporated company listed on the Nasdaq Capital Market under the trading symbol VRPX, filed a Form 8-K report with the United States Securities and Exchange Commission on September 16, 2024. The report announced the immediate resignation of Dr. Vanila M. Singh from the company's Board of Directors. Dr. Singh's departure from the board was effective as of the date of the report. The company has not provided any further details regarding the resignation or any plans for a successor.
Virpax Pharmaceuticals, Inc., a Delaware-incorporated company listed on the Nasdaq Capital Market under the trading symbol VRPX, filed a Form 8-K report with the United States Securities and Exchange Commission on September 16, 2024. The report announced the immediate resignation of Dr. Vanila M. Singh from the company's Board of Directors. Dr. Singh's departure from the board was effective as of the date of the report. The company has not provided any further details regarding the resignation or any plans for a successor.
Virpax Pharmaceuticals, Inc.是一家注册于特拉华州的公司,在纳斯达克资本市场上市,交易标的为VRPX,于2024年9月16日向美国证券交易委员会提交了8-k表格报告。报告宣布Vanila M. Singh博士立即辞去公司董事会成员的职务。Singh博士从董事会的离职日期即报告日起生效。公司未就辞职或任何接班人计划提供进一步详细信息。
Virpax Pharmaceuticals, Inc.是一家注册于特拉华州的公司,在纳斯达克资本市场上市,交易标的为VRPX,于2024年9月16日向美国证券交易委员会提交了8-k表格报告。报告宣布Vanila M. Singh博士立即辞去公司董事会成员的职务。Singh博士从董事会的离职日期即报告日起生效。公司未就辞职或任何接班人计划提供进一步详细信息。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息